Prothena provided an update on PRX012 and shared results from the Phase 1 ASCENT Clinical Program.
The Phase 1 ASCENT clinical program demonstrated proof-of-mechanism for PRX012 as a once-monthly, subcutaneous anti-amyloid beta antibody with high binding potency.
Results showed dose- and time-dependent reduction of amyloid plaque; however, with a non-competitive ARIA-E profile in early symptomatic Alzheimer's disease patients.
Proof-of-Mechanism Established
PRX012 identified as a potential once-monthly, subcutaneous anti-amyloid beta antibody with stable pharmacokinetics and low adverse reactions.
Higher ARIA-E Rates
PRX012 associated with higher ARIA-E rates compared to FDA-approved anti-A beta antibodies, potentially limiting suitability for ASCENT clinical program patients.
Feasibility of Preclinical Antibody
Prothena believes the preclinical A beta-transferrin receptor antibody may lower ARIA risk and rapidly reduce amyloid plaque with subcutaneous administration.
- The Phase 1 ASCENT clinical program results suggest potential for PRX012 as a therapeutic option for Alzheimer's disease.
- Prothena's exploration of partnership interest indicates commitment to further developing PRX012 and the preclinical PRX012-TfR antibody.
Although promising, PRX012's higher ARIA-E rates pose challenges for patient suitability. Prothena remains dedicated to advancing this innovative approach.